On June 30, 2025, Tyra Biosciences announced that the first patient has been dosed in the Phase 2 SURF302 clinical trial of TYRA-300. This study evaluates TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
TYRA-300 is an investigational, oral, FGFR3-selective inhibitor, and it is the only orally administered investigational agent in clinical development for IR NMIBC. The SURF302 study aims to assess the efficacy and safety of TYRA-300 in participants with FGFR3-altered low-grade IR NMIBC.
The company anticipates reporting initial three-month complete response (CR) data from the SURF302 study in the first half of 2026. This milestone represents a crucial step in advancing TYRA-300 for a significant unmet medical need in bladder cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.